1. |
Zhdanava M, Pesa J, Boonmak P, et al. Predictors of high healthcare cost among patients with generalized myasthenia gravis: A combined machine learning and regression approach from a US payer perspective. Appl Health Econ Health Policy, 2024, 22(5): 735-747.
|
2. |
馬駿, 林潔桓, 陳福楠, 等. 小劑量他克莫司在胸腺瘤合并全身型重癥肌無力術后的應用. 北方藥學, 2022, 19(7): 189-192.Ma J, Lin JH, Chen FN, et al. Application of low-dose tacrolimus in the postoperative management of thymoma with generalized myasthenia gravis. North Pharm, 2022, 19(7): 189-192.
|
3. |
廣東省藥學會. 圍手術期糖皮質激素醫-藥專家共識. 今日藥學, 2021, 31(10): 721-731.Expert consensus on the perioperative glucocorticoids management. Pharm Today, 2021, 31(10): 721-731.
|
4. |
中華醫學會神經病學分會神經免疫學組, 中國免疫學會神經免疫學分會. 中國重癥肌無力診斷和治療指南2015. 中華神經科雜志, 2015, 48(11): 934-940.The Chinese Medical Association Neurology Branch Immunology Group, Chinese Medical Association Neurology Branch Immunology Group. Chinese guidelines for diagnosis and treatment of myasthenia gravis 2015. Chin J Neurol, 2015, 48(11): 934-940.
|
5. |
Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med, 2022, 11(6): 1597.
|
6. |
常婷. 中國重癥肌無力診斷和治療指南(2020版). 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12.Change T. Chinese guidelines for diagnosis and treatment of myasthenia gravis (2020 edition). Chin J Neuroimmunol Neurol, 2021, 28(1): 1-12.
|
7. |
糖皮質激素急診應用共識專家組. 糖皮質激素急診應用專家共識. 中華急診醫學雜志, 2020, 29(6): 765-772.Committee of Expert Consensus on Emergency Application of Glucocorticoids. Expert consensus on emergency application of glucocorticoids. Chin J Emer Med, 2020, 29(6): 765-772.
|
8. |
Horiuchi K, Nakamura S, Yamada K, et al. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: A case series. Neuromuscul Disord, 2024, 39: 37-41.
|
9. |
Prerna M, Trapty A, Daxa V, et al. OntoMG: A unique and ontological-based intelligent framework for early identification of myasthenia gravis (MG). Int J Inf Technol, 2014, 16(6): 3847-3853.
|
10. |
Wi?ko??-D?bczyńska M, Liberacka-Dwojak M, Rzepiński ?, et al. Diurnal cognitive functioning in patients with myasthenia gravis with the role of chronotype and depression: A pilot study. Postep Psychiatr Neurol, 2024, 33(2): 49-53.
|
11. |
陳淵, 張鵬. 重癥肌無力外科治療京津冀專家共識. 天津醫藥, 2020, 48(04): 327-332.Chen Y, Zhang P. Consensus on surgical treatment of myasthenia gravis of the Jing-Jin-Ji experts. Tianjin Med J, 2020, 48(04): 327-332.
|
12. |
Frisaldi E, Ferrero B, Di Liberto A, et al. The impact of patients' pre-treatment expectations on immunosuppressive treatment outcomes in myasthenia gravis: A pilot correlational study. Muscle Nerve, 2024, 70(3): 413-419.
|
13. |
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 2016, 87(4): 419-425.
|
14. |
歐昶毅, 冉昊, 邱力, 等. 127例次重癥肌無力患者危象前狀態相關因素的分析. 中華醫學雜志, 2017, 97(37): 2884-2889.Ou CY, Ran H, Qiu L, et al. Correlation factors of 127 times pre-crisis state in patients with myasthenia gravis. Natl Med J China, 2017, 97(37): 2884-2889.
|
15. |
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002, 61(8): 718-722.
|